Estimating the economic burden of status epilepticus to the health care system

SummaryPurpose:Status epilepticus (SE) is a major neurological condition associated with significant morbidity and mortality. No studies to evaluate the cost burden of SE have been performed to date. This study estimates the direct cost related to an inpatient admission for SE in an urban academic medical center.Methods:Cases of SE were defined based on a standard 30min or greater seizure duration. The inpatient claims data were analyzed for 192 patients admitted with SE from 1 July 1993 through 30 June 1994. Patient demographic and clinical characteristics associated with increased cost were identified using multiple regression. The direct costs for SE were compared with other common DRGs.Results:The median reimbursement for a patient with SE was $8417. The average length of stay for all SE patients was 12.9 days. Age groups (17–45 and 46–64) and etiology (acute CNS) were the only patient factors significantly associated with increased cost. SE patients had 30–60% higher reimbursements than patients admitted for other acute health problems including acute myocardial infarction or congestive heart failure.Conclusions:The direct inpatient costs for SE are high compared with the direct costs of admissions for other major conditions such as acute myocardial infarction or congestive heart failure. Data from this study were used to estimate a $4 billion annual direct cost for inpatient admissions for SE. Given the incidence and the high costs, further more detailed evaluation of these costs may be useful in assessing the adequacy of reimbursement for this subset of patients with epilepsy